Abstract: Disclosed in the present application are a method and apparatus for determining PRS configuration information, which are used for implementing, in combination with preconfigured available PRS configuration information, a dynamic request for a PRS configuration, thereby improving the network efficiency and ensuring positioning accuracy. The method for determining PRS configuration information provided in the present application comprises: determining a positioning service requirement (S101); and according to the positioning service requirement, and on the basis of preset available PRS configuration information, determining PRS configuration information for a PRS resource allocation object (S102).

Abstract: Disclosed are a polyethylene glycol conjugate drug, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a polyethylene glycol conjugate drug represented by formula A or a pharmaceutically acceptable salt thereof, a method for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, and the use of the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof in the preparation of a drug.

Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

Abstract: The present application relates to the technical field of wireless communications, and discloses a terminal location capability reporting method and device. The method comprises: an access and mobility management function (AMF) entity obtains and stores a terminal location capability of a terminal, and after a location service for a target terminal arrives, if the terminal location capability of the target terminal is stored in the AMF entity, the AMF entity transmits the terminal location capability of the target terminal to a location management function (LMF) entity, so that the LMF sets a location method for the target terminal according to the terminal location capability. In the process above, when the LMF entity needs to obtain the terminal location capability of the target terminal, the terminal location capability of the target terminal can be directly obtained from the AMF entity, and there is no need to interact with the terminal to obtain the terminal location capability.

Abstract: The present invention relates to the technical field of medicines, and relates to a polyethylene glycol conjugated drug, a preparation method therefor and the use thereof. In particular, the present invention relates to a polyethylene glycol conjugated drug as shown in formula I or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug.

Abstract: A polyethylene glycol conjugate drug synergist, a preparation method therefor, and use thereof, specifically relating to a polyethylene glycol conjugate drug synergist as shown in formula I or a pharmaceutically acceptable salt thereof, a preparation method for the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylent glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, a composition containing the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof in preparation of a drug.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: An outdoor unit includes a pressure sensor for detecting an internal pressure of a first pipe. An outdoor unit controller is configured to: receive a switching signal; control an outdoor fan and a compressor to operate in a case where the switching signal instructs the outdoor unit to operate, the compressor operating at a first frequency; acquire a current state of the indoor fan in a case where the on signal instructs the outdoor unit to shut down; and control the compressor and the outdoor fan to operate if the current state of the indoor fan is an operating state, the compressor operating at a second frequency. The second frequency is lower than the first frequency. The current state of the indoor fan is obtained according to the internal pressure of the first pipe.

Abstract: The present invention relates to the technical field of medicines, and relates to a polyethylene glycol conjugated drug, a preparation method therefor and the use thereof. In particular, the present invention relates to a polyethylene glycol conjugated drug as shown in formula I or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: The disclosure relates to the technical field of medicine, specifically to a polyethylene glycol conjugated drug, a preparation method therefor and use thereof, and relates in particular to a polyethylene glycol conjugated drug represented by formula (I) or a pharmaceutically acceptable salt thereof. The disclosure further relates to a method for preparation of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof in preparation of a medicament.

Abstract: Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.

Abstract: The disclosure relates to the technical field of medicine and in particular to a polyethylene glycol conjugated drug of formula I or a pharmaceutically acceptable salt thereof. The disclosure further relates to a method for preparation and an intermediate of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof in preparation of a medicament.

Abstract: The present invention relates to the field of fuel cell stacks and stack tower or module, in particular to a sealing structure for stack tower and a stack tower. The sealing structure comprises a first component, a second component and a mica spacer, the first component and the second component are opposite to each other, the mica spacer is disposed between the first component and the second component, sealing part is arranged between the mica spacer and at least one of the first component and the second component, and the sealing part comprises a glass ceramic layer and an outer circumferential ceramic cement ring surrounding the glass cement layer; the sealing structure for stack tower has excellent sealing performance and service durability for a fuel cell system.

Abstract: Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.